Medtronic plc’s Brainsense adaptive deep brain stimulation system has been shown to be tolerable, effective and safe for long-term use at home in people with Parkinson’s disease. A study published in the Journal of the American Medical Association (JAMA) Neurology found that the majority of participants who received aDBS with the Percept neurostimulator achieved good ‘on-time’ without troublesome dyskinesia compared to standard continuous DBS therapy. Read More
The U.K. Medicines and Healthcare Products Regulatory Agency has decided to lean into personalized medicine with the adoption of the concept of a “preference zone” for determining when a therapy can and cannot be used for a specific patient, a concept that is liable to lead to more demanding postmarket surveillance. Read More
With a new drug available to slow the progression of type 1 diabetes, Sanofi SA is partnering with two med-tech companies to increase screening for early-stage type 1 diabetes and identify eligible patients. Read More
Pharma companies are collaborating to boost the power of artificial intelligence (AI) in drug discovery by allowing access to proprietary structural data to train a large language model. Each of the partners is contributing data from several thousand experimentally determined protein:ligand interactions, creating one of the most diverse datasets and the richest chemistry assembled to date for model training. Read More
Mari Serebrov, BioWorld’s regulatory editor, shares how the publication’s 35-year commitment to fact-based, expert-driven journalism helps readers navigate complexity and make informed decisions. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Astrazeneca, Remmie, Rapidemic, Rocket Doctor, Thermo Fisher. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Curonix, Hologic, Kardium. Read More
